Edward Lifesciences (NYSE: EW), an Irvine, CA-based global leader in patient-focused innovations for structural heart disease and critical care monitoring, acquired Innovalve Bio Medical Ltd., a Ramat Gan, Israel based early-stage transcatheter mitral valve replacement (TMVR) company.
The amount of the deal, expected to close by the end of 2024, was not disclosed.
Combined with Edwards’ existing mitral innovations, the acquisition enhances the company’s TMVR technologies to address structural heart patient needs and support sustainable long-term growth. Innovalve will join the transcatheter mitral and tricuspid therapies (TMTT) product group, led by corporate vice president, Daveen Chopra.
Edwards is developing a portfolio of transcatheter repair and replacement therapies designed to address mitral and tricuspid valve diseases.
FinSMEs
15/07/2024